Clinical utility of serum biomarkers in Duchenne muscular dystrophy

Abstract Assessments of disease progression and response to therapies in Duchenne muscular dystrophy (DMD) patients remain challenging. Current DMD patient assessments include complex physical tests and invasive procedures such as muscle biopsies, which are not suitable for young children. Defining alternative, less invasive and objective outcome measures to assess disease progression and response to therapy will aid drug development and clinical trials in DMD. In this review we highlight advances in development of non-invasive blood circulating biomarkers as a means to assess disease progression and response to therapies in DMD.

[1]  G. V. Ommen,et al.  Serum matrix metalloproteinase-9 (MMP-9) as a biomarker for monitoring disease progression in Duchenne muscular dystrophy (DMD) , 2011, Neuromuscular Disorders.

[2]  E. Hoffman,et al.  VBP15, a novel anti-inflammatory and membrane-stabilizer, improves muscular dystrophy without side effects , 2013, EMBO molecular medicine.

[3]  M. Wood,et al.  Expression Analysis in Multiple Muscle Groups and Serum Reveals Complexity in the MicroRNA Transcriptome of the mdx Mouse with Implications for Therapy , 2012, Molecular therapy. Nucleic acids.

[4]  M. Henry,et al.  Comparative Label-Free Mass Spectrometric Analysis of Mildly versus Severely Affected mdx Mouse Skeletal Muscles Identifies Annexin, Lamin, and Vimentin as Universal Dystrophic Markers , 2015, Molecules.

[5]  Chady H Hakim,et al.  Safe and bodywide muscle transduction in young adult Duchenne muscular dystrophy dogs with adeno-associated virus. , 2015, Human molecular genetics.

[6]  Jerry R Mendell,et al.  Report of MDA muscle disease symposium on newborn screening for Duchenne muscular dystrophy , 2013, Muscle & nerve.

[7]  A. Stark.  Determinants of the incidence of Duchenne muscular dystrophy. , 2015, Annals of translational medicine.

[8]  H. Lochmüller,et al.  Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics , 2015, Scientific Reports.

[9]  J. Ervasti,et al.  Membrane organization of the dystrophin-glycoprotein complex , 1991, Cell.

[10]  B. Wong,et al.  Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy , 2015, Neuromuscular Disorders.

[11]  J. Chamberlain,et al.  Gene therapy for Duchenne muscular dystrophy: AAV leads the way. , 2005, Acta myologica : myopathies and cardiomyopathies : official journal of the Mediterranean Society of Myology.

[12]  Asher Mullard.  EMA reconsiders 'read-through' drug against Duchenne muscular dystrophy following appeal , 2014, Nature Biotechnology.

[13]  D. Israeli,et al.  Serum profiling identifies novel muscle miRNA and cardiomyopathy-related miRNA biomarkers in Golden Retriever muscular dystrophy dogs and Duchenne muscular dystrophy patients. , 2014, The American journal of pathology.

[14]  Yetrib Hathout,et al.  Proteomic methods for biomarker discovery and validation. Are we there yet? , 2015, Expert review of proteomics.

[15]  K. Bushby,et al.  Magnetic resonance imaging in duchenne muscular dystrophy: Longitudinal assessment of natural history over 18 months , 2013, Muscle & nerve.

[16]  K. Lim,et al.  Eteplirsen in the treatment of Duchenne muscular dystrophy , 2017, Drug design, development and therapy.

[17]  E. Mercuri,et al.  Muscle histology vs MRI in Duchenne muscular dystrophy , 2011, Neurology.

[18]  K. Bushby,et al.  Dystromirs as Serum Biomarkers for Monitoring the Disease Severity in Duchenne Muscular Dystrophy , 2013, PloS one.

[19]  L. Nicholson.  Serum myoglobin in muscular dystrophy and carrier detection , 1981, Journal of the Neurological Sciences.

[20]  Kristy Brown,et al.  Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients. , 2014, Human molecular genetics.

[21]  W. Triplett,et al.  Longitudinal measurements of MRI-T2 in boys with Duchenne muscular dystrophy: Effects of age and disease progression , 2014, Neuromuscular Disorders.

[22]  E. Hoffman,et al.  Identification of Disease Specific Pathways Using in Vivo SILAC Proteomics in Dystrophin Deficient mdx Mouse* , 2013, Molecular & Cellular Proteomics.

[23]  Eric P. Hoffman,et al.  Large-scale serum protein biomarker discovery in Duchenne muscular dystrophy , 2015, Proceedings of the National Academy of Sciences.

[24]  E. Hoffman,et al.  TNF-α-Induced microRNAs Control Dystrophin Expression in Becker Muscular Dystrophy. , 2015, Cell reports.

[25]  P. Spitali,et al.  Response to: Evaluation of the serum matrix metalloproteinase-9 as a biomarker for monitoring disease progression in Duchenne muscular dystrophy , 2015, Neuromuscular Disorders.

[26]  A. Nakamura,et al.  Identification of Muscle-Specific MicroRNAs in Serum of Muscular Dystrophy Animal Models: Promising Novel Blood-Based Markers for Muscular Dystrophy , 2011, PloS one.

[27]  J. Bourke,et al.  Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study , 2011, The Lancet.

[28]  C. Zhang,et al.  Serum Creatinine Level: A Supplemental Index to Distinguish Duchenne Muscular Dystrophy from Becker Muscular Dystrophy , 2015, Disease markers.

[29]  John Bourke,et al.  Managing Duchenne muscular dystrophy – The additive effect of spinal surgery and home nocturnal ventilation in improving survival , 2007, Neuromuscular Disorders.

[30]  M. Main,et al.  Reliability of the North Star Ambulatory Assessment in a multicentric setting , 2009, Neuromuscular Disorders.

[31]  N. Itoh,et al.  Carbonic anhydrase III in serum in muscular dystrophy and other neurological disorders: relationship with creatine kinase. , 1991, Clinical chemistry.

[32]  A. Pestronk,et al.  Randomized, blinded trial of weekend vs daily prednisone in Duchenne muscular dystrophy , 2011, Neurology.

[33]  S. Peltz,et al.  THE 6-MINUTE WALK TEST AND OTHER ENDPOINTS IN DUCHENNE MUSCULAR DYSTROPHY: LONGITUDINAL NATURAL HISTORY OBSERVATIONS OVER 48 WEEKS FROM A MULTICENTER STUDY , 2013, Muscle & nerve.

[34]  C. Angelini.  The role of corticosteroids in muscular dystrophy: A critical appraisal , 2007, Muscle & nerve.

[35]  Eric P. Hoffman,et al.  Dystrophin: The protein product of the duchenne muscular dystrophy locus , 1987, Cell.

[36]  H. Hillege,et al.  European Medicines Agency review of ataluren for the treatment of ambulant patients aged 5 years and older with Duchenne muscular dystrophy resulting from a nonsense mutation in the dystrophin gene , 2015, Neuromuscular Disorders.

[37]  J. Ervasti,et al.  Dystrophin-associated glycoproteins: their possible roles in the pathogenesis of Duchenne muscular dystrophy. , 1993, Molecular and cell biology of human diseases series.

[38]  G. van Ommen,et al.  Systemic administration of PRO051 in Duchenne's muscular dystrophy. , 2011, The New England journal of medicine.

[39]  R. Finkel,et al.  Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management , 2010, The Lancet Neurology.

[40]  E. Bertini,et al.  Affinity proteomics within rare diseases: a BIO-NMD study for blood biomarkers of muscular dystrophies , 2014, EMBO molecular medicine.

[41]  F. Muntoni,et al.  204th ENMC International Workshop on Biomarkers in Duchenne Muscular Dystrophy 24–26 January 2014, Naarden, The Netherlands , 2015, Neuromuscular Disorders.

[42]  Larry Gold,et al.  Beyond antibodies: New affinity reagents to unlock the proteome , 2014, Proteomics.

[43]  E. Hoffman,et al.  Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study , 2015, Neurology.

[44]  T. Partridge,et al.  What Can We Learn From Clinical Trials of Exon Skipping for DMD? , 2014, Molecular therapy. Nucleic acids.

[45]  Nathalie Jette,et al.  A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophy , 2014, Neuromuscular Disorders.

[46]  K. Inui,et al.  Gene therapy in Duchenne muscular dystrophy , 1996, Brain and Development.

[47]  K. Davies,et al.  Therapy for Duchenne muscular dystrophy: renewed optimism from genetic approaches , 2013, Nature Reviews Genetics.

[48]  B. Wong,et al.  Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy , 2014, Neuromuscular Disorders.

[49]  Larry Gold,et al.  Advances in human proteomics at high scale with the SOMAscan proteomics platform. , 2012, New biotechnology.

[50]  S. Ebashi,et al.  Serum creatine phosphokinase. Activity in progressive muscular dystrophy and neuromuscular diseases. , 1961, Archives of neurology.

[51]  B. Wong,et al.  Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies , 2015, Human molecular genetics.

[52]  J. Mendell,et al.  Eteplirsen for the treatment of Duchenne muscular dystrophy , 2013, Annals of neurology.

[53]  E. Hoffman,et al.  Accurate Quantitation of Dystrophin Protein in Human Skeletal Muscle Using Mass Spectrometry. , 2012, Journal of bioanalysis & biomedicine.

[54]  Saptarsi M. Haldar,et al.  Glucocorticoids enhance muscle endurance and ameliorate Duchenne muscular dystrophy through a defined metabolic program , 2015, Proceedings of the National Academy of Sciences.

[55]  D. Cacchiarelli,et al.  miRNAs as serum biomarkers for Duchenne muscular dystrophy , 2011, EMBO molecular medicine.

[56]  Hanns Lochmüller,et al.  Comparative mass spectrometric and immunoassay‐based proteome analysis in serum of Duchenne muscular dystrophy patients , 2016, Proteomics. Clinical applications.

[57]  C. A. Peres,et al.  Serum creatine-kinase (CK) and pyruvate-kinase (PK) activities in Duchenne (DMD) as compared with Becker (BMD) muscular dystrophy , 1991, Journal of the Neurological Sciences.

[58]  Kristy Brown,et al.  Elusive sources of variability of dystrophin rescue by exon skipping , 2015, Skeletal Muscle.